Amneal Pharma Europe

Amneal Romidepsin FDA Approval: B2B Analysis for BD Teams and Investors

FDA · 6 min

Amneal Pharmaceuticals received FDA approval for its ready-to-use romidepsin injection solution, a competitive generic therapy for T-cell lymphomas. The 180-day CGT exclusivity positions Amneal for significant market capture, with implications for generic competition and brand dynamics.